Category: 3. Business

  • Google asks UK experts to find uses for its powerful quantum tech

    Google asks UK experts to find uses for its powerful quantum tech

    Google has announced plans to team up with the UK to invite researchers to come up with uses for the tech giant’s state-of-the-art quantum chip Willow.

    It is one of several firms competing to develop a powerful quantum computer – which is seen as an exciting new frontier in the future of computing.

    Researchers hope they will be able to crack problems in fields such as chemistry and medicine which are impossible for current computers to solve.

    Professor Paul Stevenson of the University of Surrey – who had no involvement with the agreement – told the BBC it was “great news for UK researchers”.

    The collaboration between Google and the UK’s national lab for quantum computing means more researchers will get access to the technology.

    “The new ability to access Google’s Willow processor, through open competition, puts UK researchers in an enviable position,” said Prof Stevenson.

    “It is good news for Google, too, who will benefit from the skills of UK academics.”

    Quantum devices work in a fundamentally different way to the computers powering our smartphones and laptops, solving problems using technologies based on the science of particle physics

    But the full potential of the technology has yet to be realised and the machines that currently exist have few practical applications and most are experimental.

    It is hoped giving UK researchers access to Willow would help “uncover new real world applications”.

    Scientists will be able to submit proposals describing how they intend to use the chip, and they will work with experts from Google and the UK quantum lab to design and conduct experiments.

    When it was unveiled in 2024, Google’s Willow chip was seen as a significant step forward in the field.

    Rival firms including Amazon and IBM are also developing their own tech.

    The UK has a significant quantum industry. Quantinuum, which has headquarters in Cambridge and Colorado, US, reached a $10bn (£7.45bn) valuation in September.

    Announcements of new developments from firms throughout 2025 have led some experts to believe powerful machines capable of having real-world impact will be developed within a decade.

    Dr Michael Cuthbert, Director at the National Quantum Computing Centre (NQCC) said the partnership would “accelerate discovery”.

    He said the cutting edge science it would support could ultimately lead to quantum computing being used in areas such as “life science, materials, chemistry, and fundamental physics”.

    The NQCC already hosts seven quantum computers from British-based firms such as Quantum Motion, ORCA and Oxford Ionics.

    The government says it is committing £670m to support the tech, which is a priority area in the UK’s Industrial Strategy.

    Officials believe quantum could contribute £11 billion to the UK economy by 2045.

    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.spglobal.com/energy/en/news-research/latest-news/fertilizers/121125-us-ammonia-faces-carbon-cost-hike-under-eus-cbam-draft” on this server.

    Reference #18.daa0d517.1765511624.4653773f

    https://errors.edgesuite.net/18.daa0d517.1765511624.4653773f

    Continue Reading

  • TerraUSD creator sentenced to 15 years in prison over $40bn crash

    TerraUSD creator sentenced to 15 years in prison over $40bn crash

    A former crypto entrepreneur who was behind two digital currencies that collapsed and lost an estimated $40bn ($29.9bn) has been sentenced by a New York judge to 15 years in prison for an “epic” fraud.

    Do Kwon, a South Korean national, was co-founder of Singapore-based Terraform Labs, which developed the TerraUSD and Luna digital coins.

    Kwon had admitted misleading investors about TerraUSD, a so-called stablecoin that was supposed to maintain its value against the US dollar.

    He was one of a number of crypto bosses to face charges in the US after digital tokens slumped in 2022, triggering the failure of several companies.

    US District Judge Paul A Engelmayer, who handed down the sentence, said the Stanford graduate had repeatedly lied to investors who trusted him with their money.

    “This was a fraud on an epic, generational scale,” he said during Thursday’s court hearing in Manhattan.

    “In the history of federal prosecutions, there are few frauds that have caused as much harm as you have.”

    Kwon – who pleaded guilty in August to conspiracy to defraud and wire fraud – expressed remorse to the judge.

    “I have spent almost every waking moment of the last few years thinking of what I could have done different and what I can do now to make things right,” he said.

    Prosecutors alleged that when TerraUSD fell below its $1 peg in May 2021, Kwon told investors that a computer algorithm had restored its value.

    Instead, Kwon had arranged for a trading firm to secretly buy millions of dollars of the coin to artificially boost its value, according to court documents.

    Continue Reading

  • Lundin Mining Announces TSX Approval for a Normal Course Issuer Bid

    Lundin Mining Announces TSX Approval for a Normal Course Issuer Bid

    Lundin Mining Announces TSX Approval for a Normal Course Issuer Bid

    December 11, 2025

    VANCOUVER, BC, Dec. 11, 2025 /CNW/ – (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) announces that the Toronto Stock Exchange (the “TSX”) has accepted the notice of Lundin Mining’s intention to renew its normal course issuer bid (the “NCIB”). Unless otherwise stated, all values presented are in United States dollars.

    The Company is committed to delivering shareholder returns through a balanced approach of dividends and share buybacks, with a total annual allocation of approximately $220 million. As part of its shareholder distribution policy (see news release dated March 26, 2025), the Company will pay a quarterly dividend of C$0.0275 per common share of the Company (the “Common Shares”) while allocating up to approximately $150 million per annum in share buybacks through the Company’s NCIB. If the Company allocates less than $150 million in share buybacks in a calendar year, the shortfall will be distributed as a special dividend. If applicable, the special dividend will be paid alongside the regular 4th-quarter dividend.

    Under the Company’s previous NCIB that commenced on December 16, 2024 and expires on December 15, 2025, the Company sought and received approval from the TSX to acquire up to 57,597,388 Common Shares. As of December 5, 2025, the Company acquired 17,474,000 Common Shares in the market for cancelation at an average price of C$13.09 per Common Share. Such amount includes the purchase of 14,229,000 Common Shares since January 1, 2025 in accordance with the Company’s 2025 shareholder distribution policy.

    Normal Course Issuer Bid

    The approval of the NCIB allows the Company to purchase up to 67,723,868 Common Shares, representing 10% of the 855,770,029 issued and outstanding Common Shares as of December 4, 2025, minus those Common Shares beneficially owned, or over which control or direction is exercised by the Company, the senior officers and directors of the Company and every shareholder who owns or exercises control or direction over more than 10% of the outstanding Common Shares, over a period of twelve months commencing on December 16, 2025. The NCIB will expire no later than December 15, 2026.

    All purchases made pursuant to the NCIB will be made on the open market through the facilities of the TSX, other designated exchanges and/or alternative Canadian trading systems or by such other means as may be permitted by applicable securities laws. In accordance with TSX rules, any daily purchases (other than pursuant to a block purchase exemption) on the TSX under the NCIB are limited to a maximum of 624,337 Common Shares, which represents 25% of the average daily trading volume of 2,497,350 Common Shares on the TSX for the six months ended November 30, 2025. The price that Lundin Mining will pay for Common Shares in open market transactions will be the market price at the time of purchase.

    In connection with the NCIB renewal, Lundin Mining entered into an automatic share purchase plan (“ASPP”) with its designated broker to allow for the repurchase of Common Shares at times when the Company ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules or otherwise (any such period being a “Blackout Period”). Before entering a Blackout Period, the Company may, but is not required to, instruct the designated broker to make purchases under the NCIB in accordance with the terms of the plan. At this time, the Company has not instructed the broker to actively repurchase Common Shares. Purchases made pursuant to the plan, if any, will be made by the Company’s designated broker based upon the parameters prescribed by the TSX, applicable Canadian securities laws and the terms of the written agreement entered between the Company and its designated broker. Outside of these Blackout Periods, Common Shares will be purchasable by Lundin Mining at its discretion under its NCIB.

    The ASPP will terminate on the earliest of the date on which: (i) the purchase limit under the NCIB has been reached; (ii) the NCIB expires; and (iii) the ASPP otherwise terminates in accordance with its terms. The ASPP constitutes an “automatic plan” for purposes of applicable Canadian securities legislation and the agreement governing the plan has been pre-cleared by the TSX.

    The actual number of Common Shares that may be purchased and the timing of such purchases will be determined by the Company. Decisions regarding purchases will be based on market conditions, share price, best use of available cash, and other factors. Any Common Shares that are purchased under the NCIB will be cancelled.

    About Lundin Mining

    Lundin Mining is a Canadian mining company headquartered in Vancouver, Canada with four operating mines in Brazil, Chile and the USA. We produce commodities that support modern infrastructure and electrification. Built for growth, ready for opportunity, our strategic vision is to become a top ten global copper producer. To get there, we are executing a clear growth strategy, which includes advancing one of the world’s largest copper, gold, and silver projects in the Vicuña District on the border of Argentina and Chile, where we hold a 50% interest. With a legacy of value creation in the base metals sector, Lundin Mining has a proven track record of resource growth, operational excellence, and responsible development. We are committed to safety, sustainability, and delivering long-term value for stakeholders. Lundin Mining’s shares trade on the Toronto Stock Exchange (LUN) and Nasdaq Stockholm (LUMI). Learn more at www.lundinmining.com.

    The information in this release is subject to the disclosure requirements of Lundin Mining under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on December 11, 2025 at 16:00 Pacific Time.

    Cautionary Statement in Forward-Looking Information

    Certain of the statements made and information contained herein is “forward-looking information” within the meaning of applicable Canadian securities laws. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements with respect to Lundin Mining’s shareholder distribution policy, including the payment of quarterly or special dividends, proposed NCIB, the Company’s pre-defined plan with its broker to allow for the repurchase of Common Shares and the timing, number and price of Common Shares that may be purchased under the NCIB. Words such as “believe”, “expect”, “anticipate”, “contemplate”, “target”, “plan”, “goal”, “aim”, “intend”, “continue”, “budget”, “estimate”, “may”, “will”, “can”, “could”, “should”, “schedule” and similar expressions identify forward-looking information.

     Forward-looking information is necessarily based upon various estimates and assumptions including, without limitation, the expectations and beliefs of management; assumed and future price of copper, zinc, gold, nickel and other metals; anticipated costs; ability to achieve goals; the prompt and effective integration of acquisitions; that the political environment in which the Company operates will continue to support the development and operation of mining projects; the Company will continue to pay dividends in accordance with its current shareholder distribution policy; the Common Shares will, from time to time, trade below their value; the Company will complete purchases of Common Shares pursuant to the NCIB; and assumptions related to the factors set forth below. While these factors and assumptions are considered reasonable by Lundin Mining as at the date of this document in light of management’s experience and perception of current conditions and expected developments, these statements are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: the market price of the Common Shares being too high to ensure that purchases benefit the Company and its shareholders; factors affecting the payment of dividends; and other risks and uncertainties, including but not limited to those described in the “Risks and Uncertainties” section of the Company’s MD&A for the three and nine months ended September 30, 2025 and the “Risks and Uncertainties” section of the Company’s Annual Information Form for the year ended December 31, 2024, which are available on SEDAR+ at www.sedarplus.ca under the Company’s profile.

    All of the forward-looking information in this document are qualified by these cautionary statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, forecasted or intended and readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking information. There can be no assurance that the Common Shares will, from time to time, trade below their value and that the Company will complete purchases of Common Shares pursuant to the NCIB, or that dividends will continue to be paid in the future or on the same terms currently intended by the Company. Accordingly, there can be no assurance that forward-looking information will prove to be accurate and forward-looking information is not a guarantee of future performance. Readers are advised not to place undue reliance on forward-looking information. The forward-looking information contained herein speaks only as of the date of this document. The Company disclaims any intention or obligation to update or revise forward looking information or to explain any material difference between such and subsequent actual events, except as required by applicable law.

    Lundin Mining Announces TSX Approval for a Normal Course Issuer Bid (CNW Group/Lundin Mining Corporation)

     

    SOURCE Lundin Mining Corporation

    Continue Reading

  • Pakistan names crypto as foundation for new national financial rail

    Pakistan names crypto as foundation for new national financial rail

    Pakistan’s Minister of State for Crypto and Blockchain, Bilal Bin Saqib, stated that Pakistan considers Bitcoin and digital assets to be crucial aspects that will play a significant role in the country’s new financial system, benefiting its 240 million population. This perspective highlights the potential for Pakistani officials to consider regulating the crypto market.

    This outlook was noted at the Bitcoin MENA Conference a few days after Saqib shared a statement dated Tuesday this week, declaring that the country can no longer rely on outdated economic models. Therefore, according to him, “a new engine”, which he referred to as digital assets, is needed to boost economic growth. 

    Saqib refers to digital assets as essential aspects for Pakistan’s new financial system

    During a discussion in Abu Dhabi, the senior official argued that they do not view Bitcoin, digital assets, and blockchain as speculative tools, but as an important part of their infrastructure. 

    Saqib further explained that they are not just distractions but play a significant role in establishing the basis for a new financial system for developing nations.

    Saqib, who was recently appointed Chairman of the Pakistan Virtual Assets Regulatory Authority (PVARA) and previously served as Special Assistant to the Prime Minister on Blockchain and crypto matters, highlighted that he is working towards a major goal of transforming the largest unregulated cryptocurrency markets into a favourable investment environment.

    According to him, Pakistan has the potential to develop a regulated crypto ecosystem as soon as possible, given that 70% of the population belongs to the 30-year-old age group, rather than becoming a late adopter.

    “My message is straightforward,” he stated. “If El Salvador can achieve this with 6 million people, just think about what Pakistan could accomplish with a population 40 times larger and one of the fastest-growing digital sectors in Asia.” 

    Following the senior official’s argument, analysts weighed in on the situation. They pointed out that Pakistan is increasingly becoming one of the fastest-growing cryptocurrency markets globally. 

    Their remarks came after the country moved up six spots to solidify its top position as the third in Chainalysis’ 2025 Global Crypto Adoption Index

    Pakistan positions itself as a hub for digital assets 

    Earlier this month, Saqib informed reporters that the country is preparing to establish a strategic Bitcoin reserve. He also noted that Pakistan is working towards adopting more supportive policies specifically for cryptocurrency. 

    This move sparked excitement among individuals who are advocates of cryptocurrencies. To further illustrate their commitment to exploring the crypto ecosystem, Pakistan reported allocating 2,000 megawatts of additional electricity to support Bitcoin mining activities and the construction and operation of AI data centres that same month. This time round, the country embraced national efforts essential to enable it to go digital.

    This move triggered reports to reach out to financial leaders in the country to explain this plan further. Respondingly, they mentioned that this plan aims to attract significant foreign investment and create new high-tech jobs by diverting excess power supply to AI and crypto initiatives.

    To position itself as a hub for digital assets, Pakistan notified international crypto firms in September that they are accepting applications for licenses under the country’s new federal regulations. For leading exchanges and service providers interested in exploring the market, the PVARA advised them to begin submitting their interest.

    If you’re reading this, you’re already ahead. Stay there with our newsletter.

    Continue Reading

  • ‘It’s amazing’ – the wonder material very few can make

    ‘It’s amazing’ – the wonder material very few can make

    Chris BaraniukTechnology Reporter

    Kromek Amber-coloured cadmium zinc telluride in furnace.Kromek

    Very few organisations can supply cadmium zinc telluride

    Lying on your back in a big hospital scanner, as still as you can, with your arms above your head – for 45 minutes. It doesn’t sound much fun.

    That’s what patients at Royal Brompton Hospital in London had to do during certain lung scans, until the hospital installed a new device last year that cut these examinations down to just 15 minutes.

    It is partly thanks to image processing technology in the scanner but also a special material called cadmium zinc telluride (CZT), which allows the machine to produce highly detailed, 3D images of patients’ lungs.

    “You get beautiful pictures from this scanner,” says Dr Kshama Wechalekar, head of nuclear medicine and PET. “It’s an amazing feat of engineering and physics.”

    The CZT in the machine, which was installed at the hospital last August, was made by Kromek – a British company. Kromek is one of just a few firms in the world that can make CZT. You may never have heard of the stuff but, in Dr Wechalekar’s words, it is enabling a “revolution” in medical imaging.

    This wonder material has many other uses, such as in X-ray telescopes, radiation detectors and airport security scanners. And it is increasingly sought-after.

    Investigations of patients’ lungs performed by Dr Wechalekar and her colleagues involve looking for the presence of many tiny blood clots in people with long Covid, or a larger clot known as a pulmonary embolism, for example.

    The £1m scanner works by detecting gamma rays emitted by a radioactive substance that is injected into patients’ bodies.

    But the scanner’s sensitivity means less of this substance is needed than before: “We can reduce doses about 30%,” says Dr Wechalekar. While CZT-based scanners are not new in general, large, whole-body scanners such as this one are a relatively recent innovation.

    Guy's and St Thomas' NHS Foundation Trust Wearing a white jacket, Dr Kshama Wechalekar stands alongside a hospital scannerGuy’s and St Thomas’ NHS Foundation Trust

    Dr Kshama Wechalekar with the latest scanner at London’s Royal Brompton Hospital

    CZT itself has been around for decades but it is notoriously difficult to manufacture. “It has taken a long time for it to develop into an industrial-scale production process,” says Arnab Basu, founding chief executive of Kromek.

    In the company’s facility at Sedgefield, there are 170 small furnaces in a room that Dr Basu describes as looking “like a server farm”.

    A special powder is heated up in these furnaces, turned molten, and then solidified into a single-crystal structure. The whole process takes weeks. “Atom by atom, the crystals are rearranged […] so they become all aligned,” says Dr Basu.

    The newly formed CZT, a semiconductor, can detect tiny photon particles in X-rays and gamma rays with incredible precision – like a highly specialised version of the light-sensing, silicon-based image sensor in your smartphone camera.

    Whenever a high energy photon strikes the CZT, it mobilises an electron and this electrical signal can be used to make an image. Earlier scanner technology used a two-step process, which was not as precise.

    “It’s digital,” says Dr Basu. “It’s a single conversion step. It retains all the important information such as timing, the energy of the X-ray that is hitting the CZT detector – you can create colour, or spectroscopic images.”

    He adds that CZT-based scanners are currently in use for explosives detection at UK airports, and for scanning checked baggage in some US airports. “We expect CZT to come into the hand luggage segment over the next [few] years.”

    Kromek A technician wearing blue gloves adjusts one of a line of furnaces.Kromek

    Special furnaces are needed to make CZT

    But it’s not always easy to get your hands on CZT.

    Henric Krawczynski at Washington University in St Louis in the US has used the material before on space telescopes attached to high altitude balloons. These detectors can pick up X-rays emitted by both neutron stars and plasma around black holes.

    Prof Krawczynski wants very thin, 0.8mm pieces of CZT for his telescopes because this helps to reduce the amount of background radiation they pick up, allowing for a clearer signal. “We’d like to buy 17 new detectors,” he says. “It’s really difficult to get these thin ones.”

    He was unable to source the CZT from Kromek. Dr Basu says his firm has high demand at the moment. “We support many, many research organisations,” he adds, “It’s very difficult for us to do a hundred different things. Each research [project] needs a very particular type of detector structure.”

    For Prof Krawczynski, it’s not a crisis – he says he might use either CZT that he has from previous research, or cadmium telluride, an alternative, for his next mission.

    However, there are bigger headaches at the moment. That upcoming mission was due to fly from Antarctica in December but “all the dates are in flux”, says Prof Krawczynski, because of the US government shutdown.

    Diamond Light Source A technician adjusts equipment at Diamond Light SourceDiamond Light Source

    CZT will be used in an upgrade of Diamond Light Source

    Many other scientists use CZT. In the UK, a major upgrade of the Diamond Light Source research facility in Oxfordshire – costing half a billion pounds – will improve its capabilities thanks to the installation of CZT-based detectors.

    Diamond Light Source is a synchrotron, which fires electrons around a giant ring at nearly the speed of light. Magnets cause these whizzing electrons to lose some energy in the form of X-rays, and these are directed off from the ring in beamlines so that they may be used to analyse materials, for example.

    Some recent experiments have involved probing impurities in aluminium while it melts. Understanding those impurities better could help improve recycled forms of the metal.

    With Diamond Light Source’s upgrade, due to complete in 2030, the X-rays produced will be significantly brighter, meaning that existing sensors would not be able to detect them properly.

    “There’s no point in spending all this money in upgrading these facilities if you can’t detect the light they produce,” says Matt Veale, group leader for detector development at the Science and Technology Facilities Council, which is the majority owner of Diamond Light Source.

    That’s why, here too, CZT is the material of choice.

    More Technology of Business

    Continue Reading

  • Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

    • After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI reduction: 1.73%; weight reduction: 1.42 kg; with nominal P values < 0.01). Furthermore, multiple metabolic parameters improved simultaneously.
    • Mazdutide demonstrated a favorable overall safety and tolerability profile. All enrolled subjects completed the protocol-specified visits. Throughout the study period, there were no serious adverse events (SAEs) reported in the mazdutide groups, and no subjects discontinued treatment due to adverse events (AEs).
    • there are currently no approved weight-loss medications specifically indicated for children and adolescents in China. A Phase 3 registrational clinical trial for adolescent obesity is scheduled to be initiated soon.

    SAN FRANCISCO and SUZHOU, China, Dec. 11, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that the Phase 1b clinical study of mazdutide injection (a glucagon-like peptide-1 [GLP-1] and glucagon [GCG] dual receptor agonist, R&D code: IBI362) in Chinese adolescents with obesity met its primary endpoint.

    The global issue of childhood and adolescent obesity continues to escalate. According to a UNICEF report, the global obesity rate among children and adolescents aged 5–19 has risen from 3% to 9.4% since the year 2000. Obesity has now become a more prevalent form of malnutrition than underweight, affecting one in every ten school-aged children and adolescents (approximately 188 million individuals) and placing them at risk for severe health conditions [1].

    The situation regarding obesity prevention and control among Chinese children and adolescents is equally severe. The combined detection rate of overweight and obesity among children and adolescents aged 7–18 in China surged from 1.2% in 1985 to 23.4% in 2019—an 18.1-fold increase. Notably, the obesity detection rate alone soared from 0.1% in 1985 to 9.6% in 2019, representing a staggering 75.6-fold rise [2].

    Adolescent obesity is associated with numerous long-term health risks, including hypertension, dyslipidemia, type 2 diabetes, metabolic syndrome, and psychological and behavioral issues. Furthermore, there are currently no approved weight-loss medications specifically indicated for children and adolescents in China [3], highlighting a significant unmet clinical need.

    This study is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and weight-loss efficacy of mazdutide in Chinese adolescents with obesity. A total of 36 adolescent participants (≥12 and <18 years old) with obesity were enrolled. All participants had undergone dietary and exercise intervention for at least 12 weeks prior to enrollment but achieved less than 5% reduction in body mass index (BMI). The participants met the obesity criteria specified in the Chinese national standard “WS/T 586‑2018 Screening for Overweight and Obesity in School-Age Children and Adolescents,” with a median age of 14.0 years, a mean baseline BMI of 34.12 kg/m², and a mean baseline body weight of 95.83 kg. They were randomized in a 1:1:1 ratio to receive either mazdutide 4 mg, mazdutide 6 mg, or placebo (with dose escalation) and a total treatment duration is 12 weeks.

    The study results demonstrate that mazdutide, administered via weekly multiple subcutaneous injections following a dose-titration regimen, exhibited a favorable overall safety and tolerability profile in Chinese adolescent participants with obesity. All subjects completed the protocol-specified visits. No serious adverse events (SAEs) were reported in the mazdutide treatment groups during the study period, and no subjects discontinued the study due to adverse events (AEs). The most frequently reported adverse events were gastrointestinal reactions, all of which were mild or moderate in severity. The pharmacokinetic profile of mazdutide was similar between adolescents and adults. The clinically validated safe and effective exposure range established in adults adequately covered the drug exposure levels observed with the 4 mg and 6 mg doses in adolescents.

    After the 12-week treatment period for Chinese adolescents with obesity, the mazdutide treatment groups demonstrated statistically significant reductions in both key efficacy endpoints—BMI and body weight—confirming the weight-loss efficacy of mazdutide in this population.

    Specifically, compared to baseline, the 4 mg and 6 mg mazdutide groups achieved relative reductions in BMI of 8.78% and 10.99%, and in body weight of 7.87% and 9.93%, respectively. The absolute weight reductions were 7.72 kg and 8.65 kg, respectively. These results were statistically superior to those in the placebo group (BMI reduction: 1.73%; body weight reduction: 1.19% or 1.42 kg), with all between-group comparisons reaching statistical significance (all nominal P values < 0.01). Furthermore, the 6 mg group showed numerically greater efficacy compared to the 4 mg group, suggesting a dose-dependent trend.

    Beyond weight loss, favorable trends of improvement were also observed in the mazdutide groups for multiple metabolic parameters, including waist circumference, blood pressure, blood lipids, serum uric acid, liver transaminase levels, and glycemic control indicators. These findings indicate that mazdutide may provide adolescents with obesity not only with weight reduction but also with multiple metabolic benefits.

    Based on the positive safety and efficacy results from this Phase 1b study, Innovent plans to initiate a Phase 3 registration clinical trial in adolescent participants with obesity or overweight in the near future. This initiative aims to bring this potential treatment to the large population of adolescents with obesity or overweight in China as early as possible.

    Professor Ni Xin, Principal Investigator of the study from Beijing Children’s Hospital, Capital Medical University, stated: “The issue of adolescent obesity is becoming increasingly severe, emerging as a major concern both nationally and globally. The results of this study are highly encouraging. They demonstrate that mazdutide offers a novel therapeutic approach for Chinese adolescents with obesity, characterized by potent weight-loss efficacy and a favorable safety profile. Adolescents could have better chance to adopt positive and healthy lifestyle changes supported with an effective pharmacotherapy.”

    Professor Gong Chunxiu, Principal Investigator of the study from Beijing Children’s Hospital, Capital Medical University, stated: “Treating childhood obesity is challenging. The reversal of elevated body weight through lifestyle education alone has a low success rate, and persistent obesity is prone to progression and the development of complications. Notably, the benefits brought by mazdutide, as evidenced by robust data, have demonstrated an effect that significantly surpasses weight management alone. In the study participants, we observed favorable trends of comprehensive improvement across multiple metabolic parameters, including waist circumference, blood pressure, blood lipids, serum uric acid, and blood glucose levels. This holds profound significance for potentially halting the progression from adolescent obesity to clinical obesity and metabolic syndrome in adulthood. These data reveal the advantages of mazdutide as a GCG/GLP-1 dual receptor agonist: it not only achieves effective weight loss but may also fundamentally improve the multiple metabolic disorders associated with obesity, thereby offering patients more comprehensive health benefits.”

    Dr. Lei Qian, Chief R&D Officer of General Biomedicine at Innovent Biologics, stated: “There are currently no weight-loss medications approved for children or adolescents in China. The breakthrough achieved by mazdutide in the field of adolescent obesity has robustly validated its therapeutic potential across different age groups of patients. We have observed that mazdutide reproduces the potent weight-loss efficacy and multiple metabolic benefits in adolescents that were demonstrated in adult studies. Furthermore, its pharmacokinetic profile is similar to that in adults. This provides a solid scientific foundation for its further clinical development. We will accelerate the exploration of this innovative therapy for additional indications, striving to benefit a broader population of patients with obesity across different age groups and with varying treatment needs.”

    About Mazdutide

    Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.

    Seven Phase 3 clinical studies of mazdutide have been initiated or completed, including:

    • GLORY-1: in Chinese adults with overweight or obesity;
    • GLORY-2: in Chinese adults with moderate to severe obesity;
    • DREAMS-1: in Chinese drug-naïve adults with type 2 diabetes;
    • DREAMS-2: comparing mazdutide to dulaglutide in Chinese adults with type 2 diabetes inadequately controlled with oral antidiabetic drugs;
    • DREAMS-3: comparing mazdutide to semaglutide in Chinese adults with type 2 diabetes and obesity;
    • GLORY-3: comparing mazdutide to semaglutide in Chinese adults with overweight or obesity and metabolic dysfunction-associated fatty liver disease (MAFLD);
    • GLORY-OSA: in Chinese adults with obstructive sleep apnea (OSA) and obesity.

    Among these, the first five Phase 3 clinical studies have met their primary endpoints, while the other two Phase 3 studies are ongoing.

    Furthermore, mazdutide is currently being evaluated in several additional ongoing clinical studies. These include trials investigating its use in metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), and a higher-dose head-to-head clinical study against tirzepatide for the treatment of moderate-to-severe obesity.

    *Mazdutide has received NMPA approval for two indications:

    First Indication: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

    • BMI ≥ 28 kg/m² (obesity); or
    • BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.);

    Second Indication: glycemic control in adults with type 2 diabetes:

    Monotherapy

    For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.

    Combination Therapy

    For adults with T2D who still have poor glycemic control despite:

    Diet and exercise, plus Metformin and/or sulfonylureas, or Metformin and/or SGLT2 inhibitors (SGLT2i).

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage.

    Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

    For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-looking statement

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    References

    [1] https://news.un.org/zh/story/2025/09/1140658

    [2] Prevalence trends and projection of overweight and obesity among children and adolescents aged 7-18 years in China from 1985 to 2019. Chinese Journal of Preventive Medicine, 2023, 57(4): 461-469.

    [3] Guidelines for Diagnosis and Treatment of Obesity (2024 Edition). National Health Commission of the People’s Republic of China.

    SOURCE Innovent Biologics

    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.spglobal.com/energy/en/news-research/latest-news/metals/121125-interview-italys-marcegaglia-fairly-positive-on-european-steel-demand-for-2026” on this server.

    Reference #18.dad5ce17.1765520878.13fde536

    https://errors.edgesuite.net/18.dad5ce17.1765520878.13fde536

    Continue Reading

  • Asia Stocks Rise at Open After S&P 500 Hits Record: Markets Wrap

    Asia Stocks Rise at Open After S&P 500 Hits Record: Markets Wrap

    (Bloomberg) — Asian stocks opened higher after US shares and a broader gauge of global equities hit fresh records, helped by the Federal Reserve’s third consecutive interest-rate cut.

    MSCI Inc.’s gauge of Asian shares was up 0.5% in early trading, with benchmarks in Japan and Australia rallying about 1%. Shares of SoftBank Group Corp. jumped more than 5% after people with knowledge of the matter said it is studying potential acquisitions including data center operator Switch Inc.

    The S&P 500 climbed 0.2% on Thursday. Despite the record highs, some caution for tech names persisted, as Broadcom Inc.’s shares slid in late trading after the chipmaker’s outlook for artificial intelligence revenue failed to meet investors’ lofty expectations. US stock futures were lower on Friday, with contracts on the tech-heavy Nasdaq 100 down 0.2%.

    “The momentum should continue into year-end. With rate cuts underway, a new Fed chair on deck, and earnings trending higher, the bull market looks positioned to extend into 2026,” said Gina Bolvin, President of Bolvin Wealth Management Group. “As more companies adopt AI, participation should broaden and sectors beyond the Magnificent Seven may start to show strength.”

    Thursday’s action lifted the MSCI All Country World Index — one of the broadest measures of the stock market — to a new closing high. The move placed the global equity benchmark on track for its best year since 2019.

    In Asia, Thailand markets will be in focus after Prime Minister Anutin Charnvirakul moved to dissolve parliament, setting the stage for an early election after reports of a key political party backing his minority government moving to withdraw its support.

    Yields on 10-year Treasuries edged slightly lower Friday after a small gain on Thursday. Data showed that initial jobless claims rose more than expected in the Dec. 6 week. An index of the dollar, meanwhile, traded around a two-month low.

    Elsewhere, copper climbed to a fresh record high and most other industrial metals rose as the Fed delivered the widely expected interest-rate cut and upgraded its growth forecast for the US economy. Gold and silver edged lower in Asia after rising in the previous session. Oil rose and Bitcoin flip-flopped in a tight range around $93,000.

    The tech sector also continues to be on traders’ radar after dominating much of the recent market action following Oracle Corp.’s results — which brought worries about valuations and whether heavy spending on AI infrastructure will pay off back into focus.

    While the sector has powered the global equities rally this year, overspending fears and lofty valuations have prompted some investors to rotate into other areas. Nvidia Corp. fell 1.6% on Thursday while the Magnificent Seven index of US tech giants dropped 0.6%.

    “The effect of Oracle has been greater than the Fed. This already tells us everything as we’ve been witnessing a strong concentration and one theme — AI — leading the market,” said Alberto Tocchio, a portfolio manager at Kairos Partners. “This doesn’t mean that AI is gone or it’s a bubble, but we need to focus on a wider scale.”

    Delivering a third consecutive cut, Fed Chair Jerome Powell suggested the Fed had now done enough to help stabilize the threat to employment while leaving rates high enough to continue weighing on price pressures. Traders stuck to bets on two cuts in 2026, even as the Fed’s new projections signaled only one such move.

    “The Fed’s ‘hawkish-but-bullish’ cut last night reinforces this: stronger 2026 growth, faster disinflation,” said Florian Ielpo, head of macro at Lombard Odier Investment Managers. “Cuts are continuing, but they’re no longer automatic — and that’s usually a constructive backdrop for equities.”

    Some of the main moves in markets:

    Stocks

    S&P 500 futures were little changed as of 9:22 a.m. Tokyo time Japan’s Topix rose 1.7% Australia’s S&P/ASX 200 rose 1% Euro Stoxx 50 futures rose 0.9% Currencies

    The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1744 The Japanese yen was little changed at 155.64 per dollar The offshore yuan was little changed at 7.0515 per dollar Cryptocurrencies

    Bitcoin fell 0.3% to $92,569.93 Ether fell 0.3% to $3,241.07 Bonds

    The yield on 10-year Treasuries was little changed at 4.15% Japan’s 10-year yield was unchanged at 1.930% Australia’s 10-year yield was little changed at 4.72% Commodities

    West Texas Intermediate crude rose 0.6% to $57.92 a barrel Spot gold was little changed This story was produced with the assistance of Bloomberg Automation.

    –With assistance from Joanna Ossinger and Richard Henderson.

    ©2025 Bloomberg L.P.

    Continue Reading

  • Lancet study shows new antibiotic effective against gonorrhea

    Lancet study shows new antibiotic effective against gonorrhea

    Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on Signal at hbranswell.01.

    A single-dose oral antibiotic from a new class of drugs was as effective as the previous standard of care at treating uncomplicated urogenital gonorrhea, a study published Thursday in The Lancet reported. If approved for use, zoliflodacin would be a welcome addition to an armamentarium that contains precious few tools to treat Neisseria gonorrhoeae, the wily bacterium that causes the infection.

    In fact, the world should learn soon if zoliflodacin, which is being developed as part of a private-public partnership, will be deployed in the fight against gonorrhea. The Food and Drug Administration set a decision date of Dec. 15 to tell the drug’s developers — Innoviva Specialty Therapeutics and the Global Antibiotic Research & Development Partnership, or GARDP — whether it will approve zoliflodacin.

    Earlier Thursday, the FDA approved an extension of the license for GSK’s drug Blujeba (gepotidacin) to allow its use in the treatment of uncomplicated urogenital gonorrhea. Earlier this year the antibiotic was approved for the treatment of uncomplicated urinary tract infections.

    STAT+ Exclusive Story

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    Continue Reading